Undervalued Opportunities: Penny Stocks To Watch In September 2026

Over the last 7 days, the United States market has risen by 1.6%, and over the past year, it is up 14%, with earnings forecasted to grow by 18% annually. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

Below we spotlight a couple of our favorites from our exclusive screener.

Organogenesis Holdings (ORGO)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes products for advanced wound care as well as surgical and sports medicine markets in the United States, with a market cap of approximately $185.93 million.

Operations: The company's revenue segment is entirely derived from its regenerative medicine division, which generated $457.45 million.

Market Cap: $185.93M

Organogenesis Holdings, with a market cap of US$185.93 million, faces challenges as it navigates significant revenue declines and ongoing unprofitability. Recent earnings reports highlight a steep drop in sales and increased net losses compared to the previous year. Despite these setbacks, the company maintains a stable cash runway exceeding three years and remains debt-free. Its products show promise, evidenced by positive trial results for Affinity in treating complex venous leg ulcers. However, lowered revenue guidance for 2026 indicates continued financial pressure. The company's seasoned management team may help steer through these turbulent times while pursuing new product approvals like ReNu for knee osteoarthritis treatment.

• Take a closer look at Organogenesis Holdings' potential here in our financial health report.
• Examine Organogenesis Holdings' earnings growth report to understand how analysts expect it to perform.

SNDL (SNDL)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SNDL Inc. is involved in the production, distribution, and sale of cannabis products for the adult-use market both in Canada and internationally, with a market cap of $346.88 million.

Operations: The company's revenue is derived from Liquor Retail at CA$527.02 million, Cannabis Retail at CA$328.85 million, and Cannabis Operations at CA$136.17 million.

Market Cap: $346.88M

SNDL Inc., with a market cap of CA$346.88 million, is navigating its unprofitability by reducing losses at 31.6% annually over five years and maintaining a stable cash runway exceeding three years due to positive free cash flow growth. The company remains debt-free and strategically seeks acquisitions to bolster its competitive stance in the U.S., particularly in Florida and Texas. Recent earnings show a decline in sales from CA$244.77 million to CA$235.77 million year-on-year, with net losses widening, yet SNDL has repurchased shares worth CA$32.73 million, reflecting confidence in its future prospects despite current challenges.

• Dive into the specifics of SNDL here with our thorough balance sheet health report.
• Assess SNDL's future earnings estimates with our detailed growth reports.

Protalix BioTherapeutics (PLX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its ProCellEx plant cell-based protein expression system, with a market cap of $228.82 million.

Operations: Protalix BioTherapeutics generates its revenue primarily from the biotechnology startups segment, totaling $80.62 million.

Market Cap: $228.82M

Protalix BioTherapeutics, with a market cap of US$228.82 million, has demonstrated significant financial improvement, reporting second-quarter revenue of US$19.9 million and a net income increase to US$3.78 million from the previous year's figures. The company's earnings growth over the past year is very large at 201.9%, outpacing its five-year average and the broader biotech industry growth rate. Protalix's strong financials are bolstered by a high return on equity of 26.5% and no debt burden, while its seasoned management team further supports stability in this volatile penny stock sector despite expected future earnings declines.

• Jump into the full analysis health report here for a deeper understanding of Protalix BioTherapeutics.
• Gain insights into Protalix BioTherapeutics' outlook and expected performance with our report on the company's earnings estimates.

Seize The Opportunity

• Dive into all 324 of the US Penny Stocks we have identified here.
• Curious About Other Options? Trump has pledged to "unleash" American oil and gas and these 80 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com